Want to see RNTX full AI Analyst Report?
Rein Therapeutics (RNTX) Income Statement
Rein Therapeutics Income Statement
Last quarter (Q2 2026), Rein Therapeutics's total revenue was $0.00. In Q2, Rein Therapeutics's net income was $-6.38M. See Rein Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -1.00K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 21.93M | $ 65.11M | $ 16.28K | $ 27.65K | $ 26.61K | |
| Depreciation and Amortization | $ 1.00K | $ 63.00K | $ 119.00K | $ 169.00K | $ 121.00K |
| $ -50.58M | $ -28.05M | $ 103.65K | $ 141.67K | $ 94.84K | |
| $ -21.93M | $ -65.11M | $ -16.28K | $ -27.65K | $ -26.61K | |
| $ -28.65M | $ 800.00K | $ 544.00 | $ 318.00 | $ 441.00 | |
| $ -50.58M | $ -64.31M | $ -15.73K | $ -27.33K | $ -26.16K | |
| $ -49.87M | $ -62.88M | $ -15.73K | $ -27.33K | $ -26.16K | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.96 | $ -3.51 | $ -3.42 | $ -6.02 | $ -5.89 |
| Diluted EPS | $ -1.96 | $ -3.51 | $ -3.42 | $ -6.02 | $ -5.89 |
| Weighted Average Shares Outstanding | 25.44M | 17.94M | 4.60M | 4.54M | 4.44M |
| Weighted Average Shares Outstanding (Diluted) | 25.44M | 17.94M | 4.60M | 4.54M | 4.44M |
Currency in USD